Work

Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.e21019

Authors: Katy Beckermann, Christine M. Bestvina, Jennifer G. Whisenant, Hossein Borghaei, Taofeek Kunle Owonikoko, Lynne D Berry, Yu Shyr, Chris Liang, Giovanni Selvaggi, Heather A. Wakelee, Leora Horn

Institutions: Vanderbilt University Medical Center, University of Chicago, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Fox Chase Cancer Center, Winship Cancer Institute, Xcovery (United States), Stanford Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3029698243

Cites:

Cited by: 2

Related to: 10